AxoGen (NASDAQ:AXGN) Stock Gets Price Target Increase from Canaccord Genuity Group

Key Points

• Canaccord Genuity raised AxoGen’s price target from $55 to $60 and maintained a Buy rating, implying 20.89% upside from the prior close. The broader analyst consensus is Moderate Buy, with an average target of $57.92.
• AxoGen reported quarterly results above expectations, with earnings of $0.21 per share versus a $0.13 consensus and revenue of $75.83 million versus $73.18 million expected. Management also raised its full-year revenue-growth outlook to at least 29%, or approximately $290 million.
• Despite strong recent performance and analyst optimism, AxoGen remains unprofitable, with a negative net margin and return on equity; insiders also sold $4.66 million of shares over the past three months.

AxoGen (NASDAQ:AXGN - Get Free Report) had its price target upped by analysts at Canaccord Genuity Group from $55.00 to $60.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the medical equipment provider's stock. Canaccord Genuity Group's price target suggests a potential upside of 20.89% from the company's previous close.

Several other analysts also recently commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of AxoGen in a report on Wednesday, August 26th. Citigroup restated a "market outperform" rating on shares of AxoGen in a research note on Thursday, July 30th. Wells Fargo & Company upped their price objective on shares of AxoGen from $48.00 to $56.00 and gave the stock an "overweight" rating in a research report on Thursday. Lake Street Capital reiterated a "buy" rating and set a $58.00 price objective on shares of AxoGen in a research report on Thursday. Finally, Citizens Jmp lifted their price target on shares of AxoGen from $50.00 to $55.00 and gave the stock a "market outperform" rating in a report on Thursday, July 30th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, AxoGen currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.92.

AxoGen Price Performance

Shares of NASDAQ:AXGN traded up $0.38 during midday trading on Thursday, reaching $49.63. 2,280,852 shares of the company's stock were exchanged, compared to its average volume of 1,202,146. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60. The company's 50 day simple moving average is $42.78 and its two-hundred day simple moving average is $39.28. The firm has a market capitalization of $2.67 billion, a PE ratio of -72.98 and a beta of 1.17. AxoGen has a 12 month low of $21.68 and a 12 month high of $52.91.

AxoGen (NASDAQ:AXGN - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.08. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.18 million. Equities research analysts expect that AxoGen will post -0.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other AxoGen news, Director Amy Wendell sold 13,353 shares of AxoGen stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total transaction of $646,552.26. Following the sale, the director directly owned 107,976 shares of the company's stock, valued at approximately $5,228,197.92. The trade was a 11.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph Tyndall sold 3,500 shares of AxoGen stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the transaction, the director owned 10,650 shares of the company's stock, valued at $529,305. The trade was a 24.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,503 shares of company stock valued at $4,656,947 over the last three months. Company insiders own 2.44% of the company's stock.

Institutional Investors Weigh In On AxoGen

A number of institutional investors have recently bought and sold shares of the business. Nykredit A S purchased a new stake in shares of AxoGen during the second quarter valued at $30,000. KBC Group NV purchased a new position in shares of AxoGen in the 1st quarter valued at about $41,000. Sterling Capital Management LLC raised its stake in shares of AxoGen by 858.9% during the 3rd quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider's stock worth $74,000 after buying an additional 1,589 shares during the period. State of Alaska Department of Revenue lifted its holdings in AxoGen by 16.9% during the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider's stock valued at $118,000 after purchasing an additional 409 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in AxoGen in the 2nd quarter worth about $203,000. Hedge funds and other institutional investors own 80.29% of the company's stock.

More AxoGen News

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Quarterly earnings and revenue exceeded estimates. AxoGen reported third-quarter adjusted earnings of $0.21 per share, ahead of the $0.13–$0.14 consensus range, while revenue of $75.83 million surpassed the $73.18 million estimate. Earnings also improved from $0.12 per share a year earlier. AxoGen Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects at least 29% annual revenue growth, or approximately $290 million, reinforcing the view that demand is outpacing prior expectations. AxoGen Q3 2026 Earnings and Guidance
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings. Truist lifted its target from $53 to $60 while keeping a Buy rating. Wells Fargo raised its target from $48 to $56 with an Overweight rating, and HC Wainwright increased its target from $53 to $56 while maintaining Buy ratings.
• Positive Sentiment: Options activity reflected increased bullish interest. Investors purchased 9,886 call options, nearly 11 times the typical daily volume, although options activity can also reflect short-term speculation.
• Neutral Sentiment: AxoGen’s strong year-to-date performance has prompted discussion about whether much of the improved outlook is already reflected in the stock’s valuation.
• Negative Sentiment: Despite the earnings beat, the company continues to report a negative net margin and negative return on equity, leaving profitability and execution risks for investors to monitor.

AxoGen Company Profile

AxoGen, Inc NASDAQ: AXGN is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company's product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient's body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.